Compare Global X FTSE Southeast Asia ETF (ASEA) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $1.82 |
52-Week Low | $16.86 | $0.48 |
Market Cap | — | $20.01M |
Enterprise Value | — | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
